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Abstract: Delivery of secretory immunoglobulin A (sIgA) to mucosal surfaces as a passive 
immunotherapy agent is a promising strategy to prevent infectious diseases. Recombinant 
sIgA production in plants requires the co-expression of four transcriptional units encoding 
the light chain (LC), heavy chain (HC), joining chain (JC) and secretory component (SC). 
As a way to optimize sIgA production in plants, we tested the combinatorial expression of  
16 versions of a human sIgA against the VP8* rotavirus antigen in Nicotiana benthamiana, 
using the recently developed GoldenBraid multigene assembly system. Each sIgA version 
was obtained by combining one of the two types of HC (α1 and α2) with one of the two LC 
types (k and λ) and linking or not a KDEL peptide to the HC and/or SC. From the analysis 
of the anti-VP8* activity, it was concluded that those sIgA versions carrying HCα1 and 
LCλ provided the highest yields. Moreover, ER retention significantly increased antibody 
production, particularly when the KDEL signal was linked to the SC. Maximum expression 
levels of 32.5 μg IgA/g fresh weight (FW) were obtained in the best performing 
combination, with an estimated 33% of it in the form of a secretory complex. 
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1. Introduction  
Monoclonal antibodies (mAbs) have been used in research and diagnosis for many years, and their 
application in health is increasing rapidly. They play an essential role in cancer therapy [1], however 
topical and oral immunotherapy of mucosal surfaces with mAbs is also of great interest, as it can block 
the entry and transmission of human pathogens [2–4].  
There are different expression systems available for the production of recombinant antibodies, each 
with its advantages and shortcomings. Plants are one of the most interesting platforms for recombinant 
antibody production, because they are cost-effective, highly scalable, have a low risk of contamination 
with mammalian pathogens [5–8] and also can perform post-translational modifications similar to 
mammals, as, for example, N- and O-glycosylation [9]. IgA is the most abundant antibody in mucus, 
and it forms part of the first line of defense against infectious agents. IgA can be present in the body 
fluids in its monomeric form (mIgA), containing only heavy chain (HC) and light chain (LC) or 
forming a secretory IgA (sIgA), a multiprotein structure comprising two full IgA molecules dimerized 
by a short joining chain (JC) and surrounded by the secretory component (SC), a polypeptide resulting 
from the proteolytic cleavage of the poly-immunoglobulin receptor (pIgR). IgA and, particularly, sIgA 
are good candidates for mucosal passive immunotherapy, having a number of advantages over IgG 
(e.g., the presence of four antigen binding sites, increased resistance against proteolysis in the 
gastrointestinal tract and the blocking of some bacterial pathogens mediated by carbohydrates, both in 
the HC and the SC) [2–4]. Despite this, most research effort on plant-made recombinant antibodies has 
been made on monoclonal IgG antibodies.  
The first attempt to produce a plant-made sIgA for passive immunization was the murine hybrid 
Guy’s 13 sIgG/A [10,11], which was evaluated in phase I and II clinical trials [12] as CaroxR™. Since 
then, various groups have expressed sIgA in plants [13–16]. However, there is a lack of information 
about what structural requirements are the best to produce functional, fully human sIgA in plants with 
maximum activity.  
There are a number of options available when designing a new antibody in sIgA format, which 
could lead to completely different products for the same purpose. Therefore, it is important to study 
how modifications in the engineered parts will affect antibody function. In this work, we focus on the 
study of the in vitro binding activity of the final product, although other functional considerations, such 
as in vivo activity or stability, could also be tested with an adequate setup. In the first place, there are 
several options concerning structural design: LC may occur in two isotype forms, designated kappa (κ) 
and lambda (λ), with no functional differences described between them [17], and two types of HC, 
namely the α1 and the α2. In particular, the hinge region differs significantly between the two HC 
isoforms. The hinge region of HCα1 is comprised of 23 residues, while HCα2 is made of only  
10 residues. The greater number of amino-acids in the IgA α1 provides an extended structure and a 
greater antigenic reach, while IgA α2 is more compact and, therefore, less susceptible to proteolitic 
cleavage [18].  
Secondly, subcellular localization may also affect the overall efficacy of the antibody. Targeting 
antibody chains to specific compartments in the plant cell can improve the stability, yield and/or 
downstream processing [19]. The secretory pathway appears to be the most convenient route for a 
correct antibody folding and assembly, due to the oxidizing environment of the endoplasmic reticulum 
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(ER), the low abundance of proteases and the presence of molecular chaperones. Moreover, protein 
glycosylation occurs only in the endomembrane system [20].  
Once in the secretory pathway, there are several possible options; for example, the antibody can be 
efficiently retrieved from the cis-Golgi back to the ER using a C-terminal H/KDEL retention signal or 
deposited in the vacuole [21]. Several antibodies have also been reported as apoplastic [21–24]; 
however, in some cases, retention in the ER leads to a yield improvement [25] and avoids plant 
complex glycosylation patterns that could cause an unwanted immune response [26,27]. 
An appropriate way to produce the most efficient antibody design is to perform a combinatorial 
analysis of several versions of sIgA and select those which accumulate at higher levels and/or present 
an improvement on stability and activity. With traditional DNA assembly systems, this can become 
tedious work. However, with new standard modular cloning tools, like GoldenBraid (GB) [28] or 
MoClo [29], to achieve all the combinations should be facilitated. These technologies open a new way 
for optimization of antibody production in plants by experimentally testing the best subcellular 
targeting and isotype combinations for the expression of a target antibody.  
As a proof of this concept, we have followed a combinatorial approach to optimize the plant 
production of a sIgA version of an anti-rotavirus monoclonal antibody (2A1 sIgA). The variable 
regions of 2A1 antibody were initially selected by phage display against the VP8* peptide of the VP4 
protein of the rotavirus SA11 strain capsid [30]. This antibody was previously described in its 
monomeric format, showing a strong rotavirus neutralization activity [31].  
2. Results  
2.1. GoldenBraid-Assisted Multigene Assembly of 16 Versions of Secretory IgA 
A number of standard basic DNA pieces, named GBparts, were used as a starting point in the 
building of sIgA multigene structures. Basic GBparts comprised non-coding DNA regions, as the 
CaMV 35S constitutive promoter (35s) and the strong nopaline synthase transcription terminator 
(Tnos), together with a number of GB-adapted coding sequences required for the assembly of a 
functional sIgA, namely a signal peptide derived from the tomato pectate lyase gene (SP), the constant 
regions of the human HCα1 and HCα2, the constant regions of human LCλ and LCκ, the extracellular 
region of the human SC and the complete coding sequence of the human JC. In addition, the heavy and 
light variable regions of the anti-rotavirus VP8* peptide scFv antibody fragment 2A1 were also  
GB-adapted and incorporated to the GBpart collection (Figure 1a). GB-adaptation, also called  
GB-domestication, consisted of: (i) removal of internal BsaI and BsmBI restriction sites by  
PCR-directed mutagenesis; (ii) PCR-mediated addition of flanking GB standard bar-codes, which 
consist of standard labels of 11 nucleotides that serve to facilitate cloning and, ultimately, to specify 
the relative position of each GBpart in the assembly (see Figure 1b and Table S1); and (iii) TA-cloning 
of the resulting domesticated PCR products into pGEM-T vectors.  
  
Int. J. Mol. Sci. 2013, 14 6208 
 
 
Figure 1. Assembly process of the secretory immunoglobulin A (sIgA). (a) Collection of 
basic parts necessary to construct a secretory IgA. Each basic part is cloned in a pGem-T 
vector. 35S, SP, VH-CH, VL-CL, SC, JC, Tnos, correspond, respectively, to the 35s CMV 
promoter, pectate lyase signal peptide, variable and constant regions of the heavy chain, 
variable and constant regions of the light chain, secretory component, J-chain and nopaline 
synthase terminator; (b) Example of domestication of a basic part. The 35s promoter is 
flanked by fixed BsmbI recognition-cleavage sites. The overhangs left by the BsmbI 
restriction enzyme converge with GB pDGB vectors on 5′ and on 3′, with the next basic 
part to assemble; (c) Multipartite assembly of the basic parts to form the four different 
transcriptional units: heavy chain (HC), light chain (LC), secretory component (SC) and  
J-chain (JC), into level Ω-GB destiny vectors (pDGB_1AB3 and pDGB_3AB2);  
(d) Binary assembly of transcriptional units in level α-GB destination vectors 
(pDGB_C12B and pDGB_A12C), in order to construct two different composite  
parts—IgA and JC-SC; (e) Last construct of sIgA by binary assembly of two composite 
parts in a final pDGB; (f) Example of restriction analysis of four colonies of each 
construct: left, BglII (expected bands of 2825, 1886 and 1197) and BglI (expected bands of 
2345, 1790, 1498 and 275) restriction analysis of the HC transcriptional unit; middle, BglII 
(expected bands of 4183, 2495 and 1228 kDa) restriction analysis of IgA; right, BamHI 
(expected bands of 6815, 5857 and 913 kDa) and BsaI (expected bands of 10,664 +  
2921 kDa) restriction analysis of sIgA.  
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Standard modular cloning allows the combinatorial seamless assembly of synonymous GBparts. 
Thus, 16 versions of sIgA were constructed by combining the two types of HC (HCα1 and HCα2) with 
the two versions of LC (LCκ and LCλ) and retaining or not the complex in the endoplasmic reticulum 
by adding (or not) a C-terminal KDEL signal to the HC and/or SC (see Table 1). For the assembly 
process of the four genes in a single T-DNA, the GoldenBraid cloning system was used. 
Table 1. Screening of 16 versions of sIgA by ELISA test. Anti VP8* binding activity is 
expressed in terms of Abs492 (Abs, absorbance). +++ refers to Abs > 2.0; ++ refers to  
Abs > 1.0; − refers to Abs < 0.3. 
  LCλ/SC LCλ/SCkdel LCκ/SC LCκ/SCkdel 
HCα1  ++ ++ − − 
HCα1kdel  +++ ++ − − 
HCα2  ++ ++ − − 
HCα2kdel  ++ ++ − − 
A number of steps were followed to construct each sIgA version. First, the so-called multipartite 
assembly reactions were performed. In multipartite reactions, GBparts are assembled together into 
binary destination vectors (Ω-GB vectors) to produce individual transcriptional units (TUs). To this 
end, GBparts are simply mixed together in a single tube with Ω-GB destination vector and subjected to 
a highly efficient restriction/ligation reaction, which will orderly assemble all the elements of the 
transcriptional unit together (Figure 1c). In GB multipartite assembly, properly assembled structures 
are distinguished from the initial destination plasmids using positive blue/white β-galactosidase 
selection. Multipartite assemblies comprising four individual GBparts (e.g., SC TUs) resulted in 95% 
white colonies on average, whereas 5-part GBpart assemblies (e.g., HC TUs) resulted in 85% white 
colonies on average. In all cases, four individual white colonies were selected and tested by restriction 
analysis and a minimum of three out of four colonies were found correct (see HC panel in Figure 1f as  
an example). 
Once individual transcriptional units were constructed, they were assembled together into 2-part 
TUs structures using level α-GB destination vectors in a so-called binary GB reaction. Binary reactions 
combining LC + HC produced genetic modules for the expression of full monomeric IgA (mIgA), 
whereas SC and JC TUs were also combined in a single genetic module named SC-JC (Figure 1d). 
Last, mIgA and SC-JC composite parts were assembled together into a final level Ω-GB destination 
vector in order to construct the complete sIgA (Figure 1e). The final size of the sIgA constructs was of 
13.6 kb. Binary assemblies ranged between 5% and 20% white colonies. For each construct, four 
colonies were selected for digestion, resulting in 100% correct colonies (see examples in Figure 1f). 
2.2. Transient Expression in Nicotiana benthamiana of 16 Versions of sIgA against Rotavirus  
All 16 binary plasmids containing sIgA versions against VP8* (see Table 1) were transferred to 
Agrobacterium tumefaciens and transiently transformed in Nicotiana benthamiana by means of 
agroinfiltration. For the resulting 16 plant samples, an initial screening was performed by antigen 
ELISA to detect anti-VP8* IgA activity in the clarified crude extracts of agroinfiltrated leaves using an 
anti-HC antibody for detection. To avoid potential proteolysis, protease inhibitor, PMSF, was added to 
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every extract. In order to ensure the accuracy of the comparison among all the combinations, all 
samples were equalized on the basis of the luciferase activity of a cotransformed plasmid in which the 
nopaline synthase promoter drives the luciferase gene. Antigen ELISA tests showed high anti-VP8* 
binding activity in half of the samples (Table 1). Surprisingly, a very low activity was observed in all 
sIgA versions containing the LCκ. The integrity of kappa-sIgA constructs was confirmed by  
retro-transformation of Agrobacterium plasmids into E. coli and subsequent restriction analysis and 
sequencing. In addition, the low anti-VP8* activity was confirmed in a second ELISA experiment that 
yielded similar results (not shown). Consequently, work with LCκ versions was discontinued and all 
further analyses were done with the LCλ-containing sIgA versions. 
A detailed examination of the remaining eight combinations was subsequently performed. The 
analysis was completed with TUs expressing monomeric IgA and free SC. Leaf age is a known factor 
influencing recombinant protein expression levels. When leaves of three different ages were transiently 
transformed and assayed for luciferase expression, a coefficient of variation of 22% was observed. 
Therefore, in order to increase the accuracy of the comparison, three independent leaves taken from 
different plants (leaves number 4, 5 and 6, counting from the base of the plant) were infiltrated per 
each construct. Each leaf was used as an individual biological replicate, and all results were 
subsequently normalized using a luciferase reporter system as an internal standard. The anti-VP8* 
activity of each combination was analyzed in detail by antigen-ELISA using three different detection 
tools, namely anti-HC, anti-LC and anti-SC antibodies. Antigen-ELISA tests against the HC were first 
carried out in order to give a first view of total IgA content (including mIgA and sIgA). Considerably 
high binding activity values were observed in all eight sIgA combinations, while the SC control 
remained negative. Figure 2a shows that ER retention had a positive effect, resulting in significantly 
higher anti-VP8* activity (p-value <0.01). This effect is more noticeable when the KDEL signal is 
added to the SC than to the HC, and the comparison between these two types of samples yielded also 
significant differences (p-value <0.01). The increase in anti-VP8* activity observed when the SC is 
targeted to the ER was the first evidence of the correct formation of a secretory complex. Interestingly, 
the ER-associated activity was shown to increase in a non-additive fashion, as the simultaneous 
targeting of both HC and SC to the ER did not yield significantly higher activity than individual 
targeting. A second interesting observation extracted from Figure 2a is that all the combinations 
containing HCα1 appear to be significantly more efficient than their HCα2 counterparts  
(p-value <0.01). 
The above-described results were also confirmed using anti-LC as the detecting antibody, 
confirming the presence of LC in the functional complexes detected in the previous ELISA test. 
(Figure 2b).  
Finally, antigen-ELISA tests using anti-SC as the detecting antibody were developed in order to 
specifically detect the anti-VP8* activity of sIgA complexes, as only SC-containing, VP8*-binding 
antibody complexes can be detected using this ELISA set up. Interestingly, the activity pattern 
observed for sIgA combinations was very similar to the one observed for total IgA using anti-HC 
(compare Figure 2a,c). In particular, the positive effect provided by the presence of a KDEL peptide in 
the SC was also observed using anti-SC detecting antibody, further confirming that the retention of  
the SC in the ER increases the overall anti-VP8* IgA activity by specifically stabilizing the  
sIgA subfraction. 
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Figure 2. Combinatorial analysis of eight λ versions of sIgA by ELISA tests. (a) ELISA 
assay developed with anti-HC; (b) ELISA assay developed with anti-LCλ; (c) ELISA assay 
developed with anti-SC. All plates were coated with VP8* antigen. Three different leaves 
were infiltrated and tested for each sample. Means of the three biological replicates are 
represented, with error bars representing the standard deviation. All samples were 
equalized, with the luciferase reporter system as an internal standard.  
 
Taking into account the whole analysis, the maximum anti-VP8* activity, detected both as total IgA 
and sIgA, was achieved with the HCα1-LCλ-JC-SCkdel combination. Among non-ER-retained forms, 
the maximum anti-VP8* activity was achieved with the HCα1-LCλ-JC-SC combination (Figure 2). 
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2.3. Detailed Characterization and Purification of the HCα1-LCλ-JC-SCkdel Combination  
Once the best performing combination was identified, a detailed characterization of the resulting 
product was undertaken. N. benthamiana leaves were agroinfiltrated with the best sIgA-encoding 
multigenic construct (HCα1-LCλ-JC-SCkdel). A mIgA construct (HCα1kdel-LCλ) and a free secretory 
component construct (SC) were also agroinfiltrated to be used as controls. At 5 dpi, leaves were 
harvested, and crude extracts were clarified and used for analysis. The antibody content was quantified 
by sandwich ELISA using plates coated with anti-HC antibody. mIgA control was also analyzed by 
Western blot to assess the integrity of the HC and LC when transiently produced in plants, as shown in 
Figure 3b. It was anticipated that the agroinfiltration of HCα1-LCλ-JC-SCkdel would result in a mix of 
mIgA and sIgA. The total IgA content (calculated as HC equivalents) in clarified crude extracts was 
estimated by sandwich ELISA with an anti-HC detecting antibody, whereas an anti-SC detecting 
antibody was employed to estimate the sIgA content, using a standard curve made with sIgA from 
human colostrum. As shown in Table 2, both IgA and sIgA constructs yielded similar amounts of total 
IgA, estimated as HC equivalents, namely 31.6 ± 3.7 and 32.5 ± 1.1 μg/g fresh weight (FW) and 
representing 1.1% and 1.5% of the total soluble protein (TSP) in leaves, respectively. Expectedly, only 
background sIgA values were detected for the mIgA and SC-alone constructs, whereas the  
HCα1-LCλ-JC-SCkdel construct yielded 11.0 ± 0.2 μg/g FW of sIgA (expressed as equivalents of 
HC), corresponding to a 0.5 ± 0.1% TSP. According to these calculations, it was estimated that at least 
33% of the total HC in HCα1-LCλ-JC-SCkdel-infiltrated leaves is present in the form of a sIgA 
complex (Table 2).  
Table 2. IgA/sIgA levels, calculated as HC equivalents, from clarified crude extracts, 
referred to total soluble protein (TSP) and fresh weight (FW) of the two IgA and sIgA best 
performing combinations. Means plus or minus the standard deviation of three biological 
replicates are indicated for each section. 
Construct Best Performing 
Combination 
Total IgA 
(%TSP) 
Total IgA 
(μg/g FW) sIgA (%TSP) 
sIgA  
(μg/g FW) 
IgA HCα1kdel-LCλ 1.1 ± 0.1 31.6 ± 3.7 0 0 
sIgA HCα1-LCλ-JC-SCkdel 1.5 ± 0.1 32.5 ± 1.1 0.5 ± 0.1 11.0 ± 0.2 
In principle, both mIgA and sIgA can be purified using SSL7-affinity chromatography, which binds 
the Cα2/Cα3 domain junction of the Fc (Fragment crystallizable) portion of the HC [32]. For affinity 
purification, clarified crude extracts were passed through SSL7-agarose columns. The purification 
steps were monitored by antigen-ELISA, coomassie stained SDS-PAGE and Western blot. Upon 
PAGE separation of the elution fractions, a 25 kDa band corresponding to the full size LC and a  
55 kDa band corresponding to the full size HC were observable in coomassie stained gels from IgA 
and sIgA samples, after a single step of affinity chromatography (Figure 3a). The 64 kDa coomassie 
band that would correspond to the free SC was not detected by coomassie staining, but was readily 
detectable in Western Blot analysis from sIgA samples (Figure 3d). In contrast, SSL7 control 
purifications from SC-alone and mIgA agroinfiltrations did not yield any detectable SC band  
(Figure 3d).  
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Figure 3. Characterization of SSL7-purified sIgA. (a) Coomassie stained SDS-PAGE 
under reducing conditions of elution fractions corresponding to HCα1-LCλ-JC-SCkdel 
(sIgA), HCα1kdel-LCλ (IgA) and free secretory component (SC) purification. Bands 
correspond to the heavy chain (HC) and light chain (LC); (b) Western blot analysis under 
reducing conditions of a clarified crude extract (CE) sample of HCα1kdel-LCλ (IgA) 
developed with anti-HC (left) and with anti-LC (right); (c) ELISA analysis, coated with 
VP8*, of starting clarified crude extract (CE) and elution fraction (ELU) of three samples: 
sIgA, IgA and free SC, performed as described in Figure 2. Upper panel developed with 
anti-HC, medium panel developed with anti-LC and lower panel developed with anti-SC. 
Means of three technical replicates are represented with error bars, indicating the standard 
deviation; (d) Western blot analysis under reducing conditions of the starting clarified 
crude extract (CE) and elution fractions (ELU) of three samples: sIgA, IgA and free SC. 
Upper lane developed with anti-HC, medium lane developed with anti-LC and lower lane 
developed with anti-SC; (e) ELISA analysis of fractions proceeding from gel filtration 
chromatography of a sample of SSL7-purified HCα1-LCλ-JC-SCkdel construct. Plates 
were coated with anti-HC and developed with HRP conjugated anti-HC (red) and anti-SC 
(blue). A standard curve of commercial IgA from human colostrum was obtained to 
calculate the concentration of IgA and sIgA (expressed as HC equivalents for proper 
comparison) for every fraction. 
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The anti-VP8* binding activity of the three samples was also followed by antigen ELISA. ELISA 
plates were coated with VP8*, incubated with crude and SSL7 purified extracts and developed with 
anti-HC, anti-LC and anti-SC antibodies. As expected, anti-VP8* antibody formats containing HC and 
LC peptides were detected in crude and purified samples from IgA and sIgA agroinfiltrated constructs 
(Figure 3c), whereas anti-VP8* antibody formats containing SC were only observed in crude and 
purified samples derived from the sIgA construct. No SC was detected from SC-alone constructs, 
indicating that free-SC does not bind to VP8* nor SSL7. Interestingly, the relative content of  
SC-containing antibody seems to decline after SSL7 purification (compare EC and ELU fractions of 
sIgA sample in Figure 3c, lower panel). This decline is not observed when the same samples are tested 
for their HC and LC content. Indeed, quantification of purified samples confirmed these results. Of a 
total of 0.7 μg/mL of HC, only 0.1 μg/mL were in the form of sIgA, which accounts for 21%. This 
could indicate that at least part of the secretory complex present in the clarified crude extract is 
disassembled during the purification process, losing its SC peptide and yielding monomeric  
IgA structures.  
With these results and in order to learn more about the proportion of sIgA in the total IgA, a gel 
filtration assay was performed. For this, sIgA from the best performing combination was purified and 
500 μL of the elution loaded into a prepacked high-resolution gel filtration column with a separation 
range between 10 and 600 kDa. Fractions of 250 μL were collected and monitored by sandwich ELISA 
assays developed both with anti-HC and anti-SC. Figure 3d shows two partially overlapped peaks, the 
larger one corresponding to the total content of HC equivalents (including sIgA (371 kDa), mIgA  
(146 kDa) and possibly unfolded chains) and the smaller one developed with anti-SC, corresponding to 
371 kDa sIgA (an estimated 20% of the total IgA content) (Figure 3e).  
3. Discussion  
The selection of the most appropriate isotype for recombinant antibody production in plants is 
rarely addressed using experimental approaches, as practical hurdles often override technical or 
functional considerations. Moreover, sIgA has been only occasionally considered as a feasible option 
for mucosal passive immunotherapy, despite its demonstrated appropriateness [10]. Even more, certain 
specific decisions concerning antibody design, as the choice for LC and HC isotypes or for subcellular 
localization, are rarely made on the basis of an exhaustive experimental analysis. However, it has been 
repeatedly observed that antibody expression levels diverge dramatically from case to case and that, 
e.g., the experimental selection of the most stable idiotypes, can bring considerable advantages in 
terms of yield [15,31]. 
A technical hurdle that compromises the selection among different antibody formats is the difficulty 
to produce multigenic structures that can be assayed in a combinatorial way. In the case of 
recombinant production of protein complexes in plants, the assembly of multiple transcriptional units 
in a single T-DNA is an inefficient and tedious task, particularly in the case of sIgA, which requires 
the co-expression of four TUs. As an alternative approach, some labs, including our own, have relied 
on trans- co-transformation, even though it implies reduced reproducibility and unwanted 
heterogeneity in the expression levels of the different proteins, often impeding the reach of solid 
conclusions [28]. Here, we demonstrate that the recently developed GB assembly system facilitates the 
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combinatorial assembly of the four transcriptional units necessary for sIgA expression, ensuring the 
coordinated expression of the four genes in transient expression experiments.  
In a first screening, it was determined that the use of LCκ severely reduces the activity levels of IgA 
2A1. The LCκ used in this assay was codon-optimized for Nicotiana benthamiana expression, and 
therefore, inefficient codon-usage can be discarded as a possible cause for the observed expression. 
This observation was particularly surprising and, although the integrity of the constructs containing 
LCκ were exhaustively examined, we could not find any element in the genetic design that could 
account for the low activity observed in this set of samples. Provided that LCκ have been successfully 
employed before in the production of other plant-made antibodies [33,34], it is quite possible that this 
is a specific feature of the 2A1 variable region. If so, this would highlight the importance of 
combinatorial screenings for successful plant-made antibody expression. Further experiments using 
variable regions other than 2A1 will serve to discern if the low activity of kappa light chain is an 
isotype or idiotype-specific feature. 
Detailed examination of the remaining combinations led to a number of conclusions. First, these 
experiments served as a demonstration that a fully human sIgA complex is formed in the plant cell that 
retains activity against VP8* antigen. In particular, the detection of anti-VP8* activity using an  
anti-SC detecting antibody is, to our knowledge, the strongest evidence provided so far in support for 
the formation of a fully human sIgA complex in the plant cell, as previous reports made use of hybrid 
murine IgG/A [10]. The presence of JC was not assayed, as it is technically challenging, due to the 
poor accessibility of the molecule and the lack of appropriate detecting antibodies. Therefore, the 
presence of incomplete complexes within the plant sIgA pool containing only SC bound to IgA in the 
absence of J-chain cannot be formally discarded. However, this is very unlikely, as it is well 
established that SC can only bind IgA when this is dimerized by the J-chain [35–37]. The small 
background signal observed when developing antigen-ELISA plates with anti-SC (Figure 2c) is 
probably due to un-specific binding of glycan structures within the SC, which are known to  
un-specifically bind to certain pathogens [38–40]. Also, VP8* has been previously described to bind 
glycans of the family of sialic acid [41,42]. However, plants lack this type of glycosylation, and 
therefore, it is unlikely that the observed reactivity is due to VP8* binding activity.  
In addition, it was found that IgAα1-based designs presented better results than IgAα2 in all the 
combinations tested. This is somehow surprising, because the extended hinge of the IgAα1 isotype was 
expected to result in lower stability against protease degradation, therefore leading to lower activity 
levels [43]. However, it seems that a long hinge does not suppose a handicap for this specific antibody. 
The IgAα1 hinge is O-glycosylated in animal cells with mucin-like sugars, which is thought to confer 
additional proteolytic defense [44]. Mucin-like O-glycosylation cannot be achieved natively in plant 
cells. Instead, arabinose residues linked to hydroxyproline have been reported in the hinge of  
plant-made IgAα1 [45]. Whether plant-specific O-glycosylation patterns confer additional stability to 
IgAα1 remains to be elucidated [9].  
Finally, a positive effect of ER retention in the overall anti-VP8* activity was clearly observed. It is 
well established that antibodies retained in plant ER by the addition of a KDEL signal accumulate at 
higher levels than antibodies that are secreted to the apoplast [21,22,25]. Interestingly, we observed 
that this effect is more noticeable when the KDEL signal is added to the SC. It is worthwhile to notice 
that the addition of KDEL to the SC increases both the anti-VP8* sIgA activity (as measured using 
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anti-SC antibody), as well as the overall anti-VP8* IgA activity, as detected with anti-HC and anti-LC 
antibodies. This served as an additional indication that a significant portion of the anti-VP8* IgA pool 
is present in the form of a sIgA. 
Further confirmation of the integrity of sIgA complex was obtained with the affinity purification of 
the resulting recombinant product. As shown, SC co-purifies with IgA when SSL7 is used in affinity 
binding experiments. SSL7 is reported to bind HCα between domains Cα2 and Cα3 [32,46], therefore 
discriminating between full-size IgA and Fab fragments. In the same conditions, recombinant SC alone 
was not recovered from SSL7 columns, indicating that the SC is unable to bind SSL7 on its own. 
Interestingly, the recovery rate of sIgA (as detected using an anti-SC antibody prior and after affinity 
purification) was lower than the recovery rate measured for total IgA (compare panels 1 and 2 with 
panel 3 in Figure 3c). A possible explanation is that only a fraction of the sIgAα1 complexes are 
covalently stabilized by disulfide bonds, whereas the remaining complexes are weakly kept together by 
non-covalent bonds, which can be broken apart during the purification process. Non-covalent 
complexes were previously described for native sIgAα2 [47], and therefore, it is plausible that  
non-covalent sIgAα1 complexes could occur in plants due to, e.g., partial assembly and/or 
inappropriate redox conditions in the plant ER. Although the molar ratio between SC and HC (1:4) 
could partially explain the low abundance of the SC band in purified IgA samples, the low recovery 
rate of sIgA compared to mIgA in SSL7 purification is probably contributing to these results.  
Overall, it was established that maximum anti-VP8* activity was achieved by transient 
transformation of a multigene design comprising HCα1, LCλ, KDEL-tagged SC and JC. Using this 
combination, up to 32.5 μg of HC in its different IgA assembly forms was obtained per gram of fresh 
weight, with at least one third of this amount being present in the form of sIgA. The remaining two 
thirds of measurable IgA activity do not form secretory complexes. Free SC in relative large amounts 
has been detected in all sIgA combinations (data not shown), which would suggest that SC is not a 
limiting factor in sIgA formation. Thus, it is likely that the low level of complex formation is due to 
limiting JC expression. This could be resolved by placing the JC under the control of a stronger 
promoter and/or a stronger expression system.  
Further improvements in terms of both the total IgA yield and the sIgA/mIgA ratio may be 
necessary for those applications involving high antibody doses. Moreover, additional considerations, 
such as the N- and O-glycosylation patterns of each antibody form in the context of passive mucosal 
immunotherapy, should be also considered [9]. Nevertheless, we think that the current production 
levels, combined with the high speed and combinatorial versatility of the described platform may 
provide sufficient competitive advantages for the production of monoclonal sIgAs in low-dose 
applications and/or in minimally processed formulations. 
4. Experimental Section  
4.1. Cloning and Assembly of Modular Pieces 
The DNA sequences corresponding to the constant regions of human alpha1 heavy chain (HCα1), 
alpha2 heavy chain (HCα2), lambda light chain (LCλ) and secretory component (SC) were obtained 
from Open Biosystems, Huntsville, AL, USA. Kappa light chain (LCκ) and J-chain (JC) were codon 
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optimized for Solanum lycopersicum and synthesized by GeneScript, NJ, USA (NCBI Accession 
numbers KC515402 and KC515401, respectively). The variable regions against VP8* were obtained 
from a scFv phage display, selected as described earlier [31]. The DNA module encoding the signal 
peptide for secretion was obtained by PCR from tomato SGN-U212775 unigene. Taking advantage of 
the property of seamless assembly, the junctions between the signal peptide and the coding sequences, 
e.g., HC (PSLLA-QVQLL), were tested with the signal P algorithm to ensure a correct processing into 
mature protein. PCR amplification was performed by using the Advantage-2 DNA Polymerase Mix 
(Clontech, Mountain View, CA, USA). The primers used for amplification of each basic part were 
synthesized by IDTdna, Coralville, IA, USA (Table S1). PCR was analyzed by agarose 1% gel 
electrophoresis and purified using the QIAquick PCR Purification Kit (Qiagen, Hilden, Germany). 
Amplified parts were TA cloned using the pGEM-T Easy Vector System (Promega, Madison, WI, 
USA), and 1 μL of the ligation was transformed into DH5α electrocompetent cells. Plasmid DNA 
preparations were obtained by using the E.Z.N.A. Plasmid Mini Kit I (Omega Bio-Tek, Norcross, GA, 
USA). Plasmid DNA concentration was measured using a Nano Drop Spectrophotometer 2000 
(Thermo Scientific, Rockford, IL, USA). Positive clones were selected in ampicillin-containing plates 
and confirmed by plasmid restriction analysis (EcoRI, NotI from Thermo Fisher Scientific, Waltham, 
MA, USA) and by sequencing. Assembly reactions were performed basically as described by [28] 
using BsaI and BsmBI (New England Biolabs, Ipswich, MA, USA) as restriction enzymes in 25-cycle 
digestion/ligation reactions. T4 DNA ligase was purchased from Promega. One microliter of the 
reaction was transformed into DH5α electrocompetent cells. Positive clones were selected in 
kanamycin or spectinomycin-containing plates. Plasmid DNA preparations were made by using the 
E.Z.N.A. Plasmid Mini Kit I (Omega Bio-Tek). Plasmid DNA concentration was measured using a 
Nano Drop Spectrophotometer 2000 (Thermo Scientific). Constructs were confirmed by plasmid 
restriction analysis and by sequencing. Constructs for plant functional assays were transferred to  
Agrobacterium tumefaciens electrocompetent strain GV3101 containing pSoup plasmid. 
4.2. Strains and Growth Conditions  
Escherichia coli DH5α was used for gene cloning, and Agrobacterium tumefaciens strain GV3101 
with pSoup was used for plant agroinfiltration and transformation experiments, as described in [28]. 
4.3. Plant Transient Transformation  
Agroinfiltration was performed as previously described in [48]. Briefly, overnight grown bacterial 
cultures (5 mL) were sedimented by centrifugation (15 min, 3000× g), resuspended in agroinfiltration 
buffer (AB) (10 mM MES pH 5.6, 10 mM MgCl2, 200 μM acetosyringone) and incubated for 2 h at 
room temperature (RT) on a horizontal rolling mixer. Bacterial cultures were diluted in AB to an 
optical density of 0.2 at 600 nm. Co-infiltrations of each construct with both pGreen_P19 (bushy stunt 
virus-TBSV-P19, suppressor of silencing) [28] and pGreen_Luciferase (Firefly Luciferase Genetic 
reporter under the control of a Nopaline synthase promoter and terminator) were performed by mixing 
equal volumes of the corresponding bacterial suspensions. Inoculations were carried out by  
syringe-agroinfiltration in leaves of 4–5 weeks old Nicotiana benthamiana plants (growing conditions: 
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24 °C day/20 °C night in a 16 h light/8 h dark cycle). Samples were collected 5 days post-infiltration 
and examined for transgene expression. 
4.4. Plant Material and Sample Preparation  
For sample preparation, Nicotiana benthamiana leaves were ground with a mortar and a pestle to a 
fine powder under liquid nitrogen, and the total soluble protein (TSP) was extracted with 1:3 (w:v) 
phosphate buffer saline (PBS) pH = 7.4 complemented with 0.5 mM PMSF protease inhibitor. After 
mixing, the suspension was centrifuged twice at 2 °C at 16,000× g, and the supernatant, referred to as 
clarified crude extract, was immediately used for analysis. Samples were equalized with the luciferase 
reporter system as an internal standard. Luciferase activity was determined with the Dual-Luciferase 
Reporter Assay System (Promega), following the manufacturer’s procedures, and luminescence was 
measured with a Glomax 96 microplate luminometer (Promega). 
4.5. VP8* Rotavirus Surface Protein Production  
Recombinant VP8* was obtained as described in [31]. Briefly, Escherichia coli M11 were 
transformed with Plasmid pQEVP8*, kindly provided by Monedero from Instituto de Agroquímica y 
Tecnología de Alimentos (IATA, Valencia, Spain). Purification was performed using HisTrap HP 
affinity columns (GE Healthcare, Buckinghamshire, UK), following the manufacturer’s procedures. 
4.6. ELISAs for the Quantification and Detection of VP8* Binding Activity of IgA and sIgA  
Plates (Corning, New York, NY, USA) were coated overnight at 4 °C in coating buffer (50 mM 
carbonate buffer pH 9.8) either with anti-IgA capture antibody 1:500 (Sigma-Aldrich, St-Louis, MO, 
USA) for IgA/sIgA quantification or with 10 μg/mL of recombinant VP8* for the detection of VP8* 
binding activity. Plates were then washed four times in PBS and blocked with a 2% (w/v) solution of 
ECL AdvanceTM Blocking agent (GE Healthcare) in PBS-T [0.1% (v/v) Tween 20 in PBS]. Samples 
were diluted in PBS as required for each assay and incubated for 1 h at room temperature. After 
incubation, plates were washed four times in PBS, and the antibodies for detection were added in  
PBS-T-2% blocking buffer (GE Healthcare). Four different antibodies were used for detection in 
VP8*-ELISAs: anti-HC (HRP-conjugated) 1:5000 (Sigma Aldrich, St. Louis, MO, USA), anti-LCλ 
(non-conjugated) 1:5000 (Sigma Aldrich), anti-LCκ (non-conjugated) 1:5000 (Pierce Thermo 
Scientific) and anti-SC (non-conjugated) 1:500 (Gentaur, Kampenhout, Belgium). Anti-rabbit-HRP 
(GE Healthcare) secondary antibody (1:5000) was used after the non-conjugated detecting antibodies. 
For quantification, anti-HC (HRP-conjugated) 1:5000 (Sigma Aldrich) and anti-SC (non-conjugated) 
1:500 (Gentaur, Kampenhout, Belgium) were used. Anti-rabbit-HRP (GE Healthcare) secondary 
antibody 1:5000 was also used for detection after the anti-SC detecting antibody. After four PBS 
washes, the substrate (O-phenylenediamine from Sigma Aldrich) was added, and the reactions were 
stopped with 3 M HCl. Absorbance was determined at 492 nm. The mean and SD of three samples of 
each combination were calculated for every VP8*-ELISA. A standard curve of HC content in a 
commercial IgA obtained from human colostrums (Sigma-Aldrich) was used to calculate the HC 
content in IgA/sIgA samples. The same standard was used to estimate the sIgA content in  
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sIgA-containing samples using anti-SC as the secondary antibody. To facilitate comparisons, all 
antibody concentrations were provided as equivalents of HC. Three replicates were analyzed per each 
experimental point, and the mean ± SD was calculated. 
4.7. SDS-PAGE and Western Blot Analysis 
Proteins were separated by SDS/PAGE in 10% denaturing gels (Invitrogen, Carlsbad, NM, USA). 
Gel staining was carried out with coomassie following standard procedures. For Western blot analysis, 
blots were incubated with 1:20,000 anti-HC (Sigma Aldrich), 1:10,000 anti-LC (Sigma Aldrich) or 
anti-SC 1:5000 (Gentaur), followed by 1:20,000 μg/mL HRP-conjugated anti-rabbit IgG secondary 
antibody (GE Healthcare) for the detection of the LC and SC. Blots were developed with an ECL Plus 
Western Blotting Detection System (GE Healthcare). 
4.8. SSL7 Affinity Purification  
The SSL7 protein specifically binds the hydrophobic interface between the Cα2 and Cα3 domains 
of the Fc portion of the HC. Protein extracts, prepared as explained previously, were further clarified 
using a 0.22 μm Stericup (Millipore, Billerica, MA, USA) on ice. Purification steps were performed as 
previously described by [31].  
5. Conclusions 
We show here the feasibility of combinatorial optimization of sIgA production in plants using 
GoldenBraid DNA cloning technology. Moreover, we demonstrate that a fully human sIgA is 
assembled in the plant cell, and that the maximum yields of the anti-rotavirus sIgA2A1 used in  
this study are obtained when HCα1 and LCλ are used in combination with an ER-retained  
secretory component. 
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